75 related articles for article (PubMed ID: 37185610)
1. The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.
Kane E; Painter D; Smith A; Crouch S; Oliver S; Patmore R; Roman E
Cancer Epidemiol; 2019 Apr; 59():236-243. PubMed ID: 30844679
[TBL] [Abstract][Full Text] [Related]
2. How do you define treatment success in MZL?
Casulo C
Blood; 2024 Feb; 143(5):382-383. PubMed ID: 38300612
[No Abstract] [Full Text] [Related]
3. Correction to: A transformation perspective on marginal and conditional models.
Biostatistics; 2024 Apr; 25(2):597. PubMed ID: 37531618
[No Abstract] [Full Text] [Related]
4. Marginal zone lymphomas.
Zucca E; Rossi D; Bertoni F
Hematol Oncol; 2023 Jun; 41 Suppl 1():88-91. PubMed ID: 37294969
[TBL] [Abstract][Full Text] [Related]
5. Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma).
Nathwani BN; Drachenberg MR; Hernandez AM; Levine AM; Sheibani K
Semin Hematol; 1999 Apr; 36(2):128-38. PubMed ID: 10319381
[TBL] [Abstract][Full Text] [Related]
6. Transformation of marginal zone lymphoma (and association with other lymphomas).
Casulo C; Friedberg J
Best Pract Res Clin Haematol; 2017; 30(1-2):131-138. PubMed ID: 28288708
[TBL] [Abstract][Full Text] [Related]
7. Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study.
Kalashnikov I; Tanskanen T; Viisanen L; Malila N; Jyrkkiö S; Leppä S
Blood Cancer J; 2023 Apr; 13(1):62. PubMed ID: 37185610
[TBL] [Abstract][Full Text] [Related]
8. Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A population-based study.
Du Y; Wang Y; Li Q; Chang X; Shen K; Zhang H; Xiao M; Xing S
Int J Cancer; 2024 Mar; 154(6):969-978. PubMed ID: 37874120
[TBL] [Abstract][Full Text] [Related]
9. Transformation risk and associated survival outcome of marginal zone lymphoma: A nationwide study.
Sun X; Li H; Yang Y; Wu Y; Kang K; Liu Q; Luo R; Wang L; Zhao A; Niu T
Ann Hematol; 2024 Mar; ():. PubMed ID: 38459154
[TBL] [Abstract][Full Text] [Related]
10. Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study.
Kalashnikov I; Tanskanen T; Pitkäniemi J; Malila N; Jyrkkiö S; Leppä S
Blood Cancer J; 2021 Dec; 11(12):203. PubMed ID: 34923571
[TBL] [Abstract][Full Text] [Related]
11. A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics.
Bult JAA; Huisman F; Zhong Y; Veltmaat N; Kluiver J; Tonino SH; Vermaat JSP; Chamuleau MED; Diepstra A; van den Berg A; Plattel WJ; Brink M; Nijland M
Blood Cancer J; 2023 Sep; 13(1):130. PubMed ID: 37658062
[TBL] [Abstract][Full Text] [Related]
12. Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018).
Auñón C; Sanvisens A; Turon E; Vidal-Vila A; Puigdemont M; Osca-Gelis G; Eraso A; Marcos-Gragera R
Cancer Med; 2023 Jun; 12(11):12343-12353. PubMed ID: 37076996
[TBL] [Abstract][Full Text] [Related]
13. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study.
Tun AM; Khurana A; Mwangi R; Link BK; Wang Y; Feldman AL; Thompson CA; Novak AJ; Villasboas JC; Thanarajasingam G; Farooq U; Syrbu S; Nowakowski GS; Witzig TE; Ansell SM; Rimsza LM; Cerhan JR; Habermann TM; Maurer MJ
Blood Adv; 2022 Sep; 6(17):5210-5221. PubMed ID: 35849723
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
